Eiger BioPharmaceuticals, Inc.

OTCPK:EIGR.Q 株式レポート

時価総額:US$4.9m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Eiger BioPharmaceuticals バランスシートの健全性

財務の健全性 基準チェック /06

Eiger BioPharmaceuticals has a total shareholder equity of $-14.5M and total debt of $41.1M, which brings its debt-to-equity ratio to -284.4%. Its total assets and total liabilities are $38.8M and $53.3M respectively.

主要情報

-284.4%

負債資本比率

US$41.12m

負債

インタレスト・カバレッジ・レシオn/a
現金US$25.84m
エクイティ-US$14.46m
負債合計US$53.28m
総資産US$38.83m

財務の健全性に関する最新情報

Recent updates

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 01
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Jan 04
The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Dec 20
Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Nov 09
Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Oct 06
Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Oct 05

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

Sep 06

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

Jul 26

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Jul 20

Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon

Apr 06

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be

Mar 15
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be

Eiger Pharma: HDV Approval In 2023 Is A Major Catalyst

Dec 26

財務状況分析

短期負債: EIGR.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

長期負債: EIGR.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


デット・ツー・エクイティの歴史と分析

負債レベル: EIGR.Q has negative shareholder equity, which is a more serious situation than a high debt level.

負債の削減: EIGR.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


貸借対照表


キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: EIGR.Q has less than a year of cash runway based on its current free cash flow.

キャッシュランウェイの予測: EIGR.Qは、フリーキャッシュフローが毎年12.8 % の歴史的率で減少し続ける場合、キャッシュランウェイが 1 年未満になります。


健全な企業の発掘